144060-62-8

Basic information

• Product Name: Febuxostat Impurity 8
• Synonyms: Febuxostat Impurity 8;Febuxostat ImpurityF;Febuxostat Impurity L;FeBuxostat Impurity 29;Febuxostat Impurity Z19
• CAS NO: 144060-62-8
• Molecular Formula: C₁₆H₁₇NO₄S
• Molecular Weight: 319.37548
• Mol File: 144060-62-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 535.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.268±0.06 g/cm3(Predicted)
• PKA: 1.22±0.37(Predicted)
• CAS DataBase Reference: Febuxostat Impurity 8(CAS DataBase Reference)
• NIST Chemistry Reference: Febuxostat Impurity 8(144060-62-8)
• EPA Substance Registry System: Febuxostat Impurity 8(144060-62-8)

Safety Data

• Hazardous Substances Data: 144060-62-8(Hazardous Substances Data)

Usage

Uses

3-Descyano-3-formyl Febuxostat is an impurity of Febuxostat (F229000), a xanthine oxidase/xanthine dehydrogenase inhibitor that is used for treating hyperuricemia and chronic gout.

Upstream product

• 161797-99-5 (2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester) 
• 1380049-41-1 2-(3-formyl-4-hydroxyphenyl)-N,N,4-trimethylthiazole-5-carboxamide 
• 1380049-39-7 2-(4-hydroxyphenyl)-N,N-4-trimethylthiazole-5-carboxamide 
• 1380049-42-2 2-[3-formyl-4-(2-methylpropoxy)phenyl]-N,N-4-trimethylthiazole-5-carboxamide 
• 161798-01-2 ethyl 2‐(3‐formyl‐4‐hydroxyphenyl)‐4‐methylthiazole‐5‐carboxylate 
• 161798-03-4 2-(3-formyl-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 
• 144060-97-9 ethyl 2-(4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate 
• 20524-86-1 dichloromethyl ether 

Downstream Products

• 144060-53-7 febuxostat 
• 161798-03-4 2-(3-formyl-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 
• 1350352-74-7 2-[3-formyl-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid n-butylamine 
• 1350352-73-6 2-[3-formyl-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid methylamine 

Relevant articles and documents

AN IMPROVED PROCESS FOR PREPARATION OF FEBUXOSTAT AND ITS POLYMORPHIC CRYSTALLINE FORM C THEREOF

The present invention relates to process of preparation of 2-(3-cyano-4- isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid (Febuxostat). The present invention in particular relates to an efficient and easily to operate scalable process of manufacturing of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid (Febuxostat) of Formula I and its crystalline polymorphic Form C.

PROCESS FOR THE PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to novel and improved processes for the preparation of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1 and its pharmaceutically acceptable salts thereof. the present invention also provides the novel process for the preparation of crystalline forms of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1 and its intermediates.

2-arylthiazole derivatives and pharmaceutical composition thereof

Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): STR1 wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.